Current Allergy and Clinical Immunology - March 2008

More documents

Recommendations

Info

$latex allerGy revisited : a review - Allergy Society of South Africa$

$Cross-reactivity of food allegens with latex - ALLSA$

CPD QUESTIONNAIREEarn 2 CPD points after you have read the journal by completingthe following questionnaire online on the ALLSAwebsite at www.allergysa.org/cpd or follow the links fromthe home page. To earn points, you will need to registerand fill in personal details (make sure you have yourHPCSA number handy and decide on a password beforehand).Once you have registered, you can answer thequestionnaire. If you have registered for a previous questionnaire,you'll need your HPCSA number and passwordto logon. Please note that there is only one correct answerper question, and you will have only one opportunity tosubmit the questionnaire, so please check answers carefully.You will be able to change anwers if you click thewrong one by mistake, but once you click 'SubmitAnswers' the test will be submitted and marked.Points will be submitted electronically to the HPCSA.The closing date for submission of this questionnaire is 30June 2008.IMMUNODEFICIENCY DISEASES PRESENTING INADULTS – DIAGNOSIS AND MANAGEMENT1. True or false: Primary immune deficiency is alwaysdiagnosed in childhood and never presents for the firsttime in adults.a) Trueb) False2. True or false: Recurrent localised infections are astrong indication of underlying systemic immunedefect.a) Trueb) False3. True or false: Antibody deficiency is more common inadults than primary cellular immune defects.4. True or false: The commonest diagnosis for immunedeficiency in adult patients is common variablehypogammaglobulinaemia (CVH) which can involveboth humeral and cellular immunity.APPROACH TO THE CHILD WITH RECURRENT INFEC-TIONS – PRESENTATION AND INVESTIGATION OFPRIMARY IMMUNODEFICIENCY1. Choose ONE incorrect answer: Contributing factorsfor recurrent infections in childhood include:a) Exposure to smoke in the homeb) Day care attendance of the childc) Schoolgoing siblings in the homed) Breastfeeding (HIV-negative mother)e) Gastro-oesophageal refluxf) Anatomical obstructions2. Choose ONE incorrect answer: Cost-effective firststage initial laboratory or side room investigations inSouth Africa for a child with recurrent respiratory infectionsincludesa) Full blood count and differentialb) Immunoglobulin isotypes G, M, A, and Ec) HIV testingd) Mantoux skin teste) Lymphocyte proliferationsf) Sweat test3. Choose ONE incorrect answer:a) Deficient antibody response can occur despite normallevels of serum IgG.b) Recurrent meningococcal infections point towardsphagocyte defects.c) Absence of tonsillar tissue in the presence of recurrentbacterial infections may give a clue to defectiveB-lymphocyte development.d) X-linked agammaglobulinaemia is clinically expressedin males.e) An ulcerating BCG can be a warning sign of lack ofcellular immunity.SEVERE COMBINED IMMUNODEFICIENCY (SCID)1. True or false: All children who have SCID can be diagnosedby an absolute lymphocyte count after birth.a) Trueb) False2. True or false: The most common type of SCID isX-linked and is due to a deficiency of the commongamma chain.a) Trueb) False3. True or false: SCID should be suspected in any childwho presents early in life with severe or opportunisticinfections.a) Trueb) FalseAN UPDATE OF THE PRIMARY ANTIBODY DISORDERS1. True or false: True or false: Arrest in early B-cell developmentresults in decreasing B-lymphocyte numbersand profoundly reduced immunoglobulin isotypeconcentrations.a) Trueb) False2. True or false: Common variable immunodeficiency is aheterogenous group of diseases associated with complementdeficiencies.a) Trueb) False3. True or false: Patients with X-linked Hyper-IgMsyndrome may present with serious Pneumocystisjeroveci or Cryptosporidium infections.a) Trueb) False4. True or false: For many primary antibody deficienciesintravenous immunoglobulin G replacement therapy isthe treatment of choice.a) Trueb) FalseINTRAVENOUS IMMUNOGLOBULIN1. True or false: All IVIG preparations are equally efficacious.a) Trueb) False2. True or false: IVIG is a recommended treatment optionfor haemolytic disease of the newborn.a) Trueb) False3. True or false: The usual dose of IVIG for antibodyreplacement therapy is between 400 and 600 mg/kgevery 2-4 weeks.a) Trueb) FalseEPOXY RESIN EXPOSURE AND DERMATITIS – A CASESTUDY1. True or false: In rare cases depigmentation can resultfrom exposure to epoxy resins and is referred to as‘leucoderma’.a) Trueb) False2. True or false: Exposure to the organic solvents that areadded to some epoxy products can cause allergic contactdermatitis.a) Trueb) False3. True or false: ACD, ICD, CU, leucoderma, but not respiratoryreactions may result from exposure to epoxyresins.a) Trueb) FalseAccredited by the Colleges of Medicine of South AfricaCurrent Allergy & Clinical Immunology, March 2008 Vol 21, No. 1 59
INSTRUCTIONS FOR AUTHORSCurrent Allergy & Clinical Immunology publishesarticles concerned with the understanding andpractice of allergic diseases or clinical immunology.Material submitted for publication to CurrentAllergy & Clinical Immunology is accepted oncondition that it has not been published elsewhere.The management reserves the copyrightof the material published. All named authorsmust give consent to publication. Current Allergy& Clinical Immunology does not hold itselfresponsible for statements made by contributors.Original research, review articles, case reports,brief research reports or photographs may be submitted.Letters to the editor are welcome and ifsuitable will be published in a correspondence section.All articles will be subject to peer review.Electronic submission is preferable. However, ifauthors are unable to submit electronically then thearticle may be posted to the correspondenceaddress listed at the end of these instructions.Manuscript preparation1. Articles may be submitted electronically onlineat www.allergysa.org/articles or follow thelinks from the homepage www.allergysa.org.To register, you need to enter your name, personaldetails, HPCSA number and a password.Once you have registered, you will receive anemail confirming your registration. You caneither submit your article immediately or logon at a later date. Authors should state theirfull name, qualifications, institutional affiliationand provide a corresponding address andemail on the title page. Articles should be amaximum of 3500 words with no more than 3figures and 3 tables. Short reports should be amaximum of 1000 words with a maximum of2 tables or illustrations. Case reports shouldnot exceed 2000 words, with a maximum of 3figures, 3 tables and 10 references, and shouldconform to the usual structure: abstract (notmore than 50 words), introduction, methods,results, discussion.2. Each article should be accompanied by a summaryof not more than 200 words (50 words forshort reports). A structured abstract is requiredfor original research papers.3. Authors are requested to declare conflict ofinterest and source of funding relating to thearticle. Authors should disclose any relationshipwithin the last 2 years with pharmaceuticalcompanies in the following categories ifpertinent to the article: research grants, educationalsupport (sponsorship at conference),advisory boards, speaker, consultant or sharesin companies. This must be stated at the endof the manuscript before the references.Details of ethical approval obtained must beincluded in all original research articles.4. All abbreviations should be spelt out when firstused in the text and thereafter used consistently.5. Scientific measurements should be expressed inSI units.6. Tables should be labelled with Roman numerals,thus: I, II, III, etc. and illustrations withArabic numerals, thus: 1, 2, 3, etc. Tables andfigures should be submitted as part of the manuscriptfile. Please do not submit photographsin Powerpoint and MS Word format – a highresolutionjpg is required. Photographs shouldbe submitted separately from the manuscriptfile and clearly labelled.7. Where identification of a patient is possible froma photograph the author must submit a consentto publication signed by the patient, or by theparent or guardian in the case of a minor.8. If any tables or illustrations submitted have beenpublished elsewhere, written consent to republicationshould be obtained by the author fromthe copyright holder and the author(s).References1. References should be inserted in the text assuperior numbers, and should be listed at theend of the article in numerical order.2. References should be set out in the Vancouverstyle, and only approved abbreviations of journaltitles should be used; consult the January issueof Index Medicus (No. 1 Part 1) for these details.Names and initials of all authors should be givenunless there are more than six, in which case thefirst three names should be given followed by ‘etal.’ First and last page numbers should be given.Example:1. Khakoo G, Lack G. Recommendations forusing MMR vaccine in children allergic toeggs. BMJ 2000; 320: 929-932.3. References for books should include author,title, town, publisher and date.Example:1. Abbas AK, Lichtman AH. Basic Immunology.Philadelphia: WB Saunders, 2001.4. ‘Unpublished observations’ and ‘personal communications’may be cited in the text, but not inthe reference list. Articles accepted but not yetpublished can be included as references followedby ‘(in press)’.All correspondence should be addressed to:The Editors, Current Allergy & Clinical Immunology,Allergy Society of South Africa, PO Box 88,Observatory 7935, South Africa.E-mail: allsa@mweb.co.za60 Current Allergy & Clinical Immunology, March 2008 Vol 21, No. 1
Page 6 and 7: with memory T-cell phenotypes. 18 T
Page 8 and 9: Burkholderia cepacia may be serious
Page 10 and 11: Fig. 4. Sweat test.Stage 3Lymphocyt
Page 12 and 13: AN UPDATE OF THE PRIMARY ANTIBODYDI
Page 14 and 15: lymphocytes refine the primary anti
Page 16 and 17: ange of haematological problems occ
Page 19 and 20: SEVERE COMBINED IMMUNODEFICIENCY(SC
Page 21 and 22: tinely from all neonates at birth i
Page 23 and 24: tions to the use of antiviral drugs
Page 25 and 26: therapeutic IVIG are complex. In ma
Page 27 and 28: TABLE III. Recommendations for the
Page 29 and 30: 5. Ballow M. Mechanisms of action o
Page 31 and 32: Fig. 2. Surface epidermis with unde
Page 33 and 34: sone). Unfounded steroidophobia is
Page 35 and 36: tant reaction fades by 72 hours. Fo
Page 37 and 38: try worker: case report and review
Page 39 and 40: ➞Step up if needed (first check i
Page 41 and 42: NEWSALLSA hosts a symposium at the
Page 43 and 44: PRODUCT NEWSNEW DESIGN FOR SYMBICOR
Page 45 and 46: PRODUCT NEWSBOEHRINGER INGELHEIM LA
Page 47 and 48: PRODUCT NEWSNASONEX IS NOW INDICATE
Page 49: PRODUCT NEWSNew Nestlé NAN H.A. 1

Current Allergy and Clinical Immunology - March 2008

Create successful ePaper yourself

Delete template?

Save as template?